INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

In-Person Breakfast Event at the AAD – Spotlight on Hidradenitis Suppurativa

Ana Palijan, PhD

Ana Palijan, PhD

Director, Early Phase and Translational Research

Author picture

Innovaderm was in New Orleans for the 2023 edition of the AAD congress and hosted its 4th Breakfast Event: Spotlight on Hidradenitis Suppurativa (HS).

Listen to our world-renowned dermatology key opinion leaders’ presentations to learn about HS and the latest research findings:

  • Dr. Amit Garg, MD​ – Challenges of Current Scales & Development of Novel Strategies
  • Dr. Alexa B. Kimball, MD, MPH – 2023 HS Therapeutic Update
  • Dr. James Krueger, MD, PhD – Promising Molecular Targets for Treatment of HS

 

 

 

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.